Tucked within the introns of PLCE1 on chromosome 10, rs10882398 marks a variant that influences blood pressure across the lifespan and reaches its most dramatic clinical expression during pregnancy. PLCE1 (phospholipase C epsilon 1) encodes an enzyme that hydrolyzes membrane phospholipids to generate second messengers — primarily IP3 (inositol trisphosphate) and diacylglycerol¹¹ IP3 (inositol trisphosphate) and diacylglycerol
IP3 triggers calcium release from intracellular stores; DAG activates protein kinase C — together they regulate vascular smooth muscle tone, podocyte survival, and endothelial function. The A allele at this locus nudges systolic blood pressure upward, amplifies risk for preeclampsia, and — through the kidney's filtration cells — leaves carriers less able to tolerate the haemodynamic demands of hypertension.

The Mechanism

PLCE1 is expressed in two cell types that directly regulate vascular pressure and renal filtration: glomerular podocytes²² glomerular podocytes
the specialized foot-process cells that form the kidney's filtration barrier; podocyte loss is a hallmark of hypertensive kidney disease and arteriolar smooth muscle cells in the kidney glomerulus. In endothelial cells it operates downstream of Rap-1 signaling to elevate intracellular calcium via the IP3 pathway, driving prostacyclin (PGI2) synthesis — an endogenous vasodilatory and antithrombotic mediator.

When PLCE1 function is compromised, two pathways toward elevated pressure are implicated. First, impaired endothelial PLCε-to-calcium signaling reduces PGI2 output, tipping the prostanoid balance toward vasoconstriction. Second, the kidney's pressure-buffering capacity diminishes: in mice, PLCE1 deficiency produces no renal phenotype at normal blood pressure but causes 20-fold increased albuminuria, glomerulosclerosis, and podocyte loss when hypertension is induced³³ 20-fold increased albuminuria, glomerulosclerosis, and podocyte loss when hypertension is induced, consistent with a genotype that tolerates normal pressures but amplifies injury under stress. During pregnancy, the haemodynamic demands of placentation — which normally require spiral artery remodelling and careful blood pressure management — may expose this vulnerability acutely.

rs10882398 is an intronic variant and does not change the PLCE1 protein sequence. It is a tag SNP marking a regulatory haplotype that modifies PLCE1 expression levels or splicing in relevant tissues. The exact molecular mechanism by which this haplotype reduces PLCE1 function has not been characterized at the biochemical level.

The Evidence

The blood pressure association is genome-wide significant and replicated across hundreds of thousands of participants. The GWAS Catalog records an A-allele association with systolic blood pressure at p=9×10⁻²³ (beta=0.019 mmHg per A allele), and with preeclampsia/pregnancy-induced hypertension combined at OR=1.11 (95% CI 1.08–1.14; p=2×10⁻¹³).

Tyrmi et al., JAMA Cardiology 2023⁴⁴ Tyrmi et al., JAMA Cardiology 2023 conducted the largest preeclampsia GWAS to date, combining 16,743 women with preeclampsia from the Finnish FINNPEC and FinnGen cohorts, the Estonian Biobank, and the international InterPregGen consortium. Among 19 genome-wide significant associations — 13 of them novel — PLCE1 was identified as one of seven loci carrying genes previously known to regulate blood pressure (alongside NPPA, NPR3, TNS2, FURIN, RGL3, and PREX1), reinforcing the concept that preeclampsia shares genetic architecture with essential hypertension.

Changalidis et al., Genes 2022⁵⁵ Changalidis et al., Genes 2022 confirmed the rs10882398 signal independently: a meta-analysis of FinnGen and UK Biobank GWAS summary statistics across 24 pregnancy complications identified rs10882398 in PLCE1 as one of three loci reaching genome-wide significance (p=8.9×10⁻⁹) for pregnancy hypertension.

The mechanistic evidence for PLCE1 in blood pressure comes from Atchison et al., American Journal of Physiology Renal Physiology 2020⁶⁶ Atchison et al., American Journal of Physiology Renal Physiology 2020: PLCE1-null mice develop severe glomerulosclerosis under experimentally induced hypertension, with albuminuria 20-fold above wild-type controls, establishing a clear gene-dose relationship between PLCE1 status and pressure-mediated kidney injury.

Practical Actions

For A-allele carriers, the clinically actionable implications run in two directions: blood pressure control is more protective than average because the PLCE1-deficient kidney is disproportionately sensitive to elevated pressure; and pregnancy represents a period of amplified cardiovascular risk requiring proactive monitoring.

Dietary sodium restriction achieves measurably larger blood pressure reductions in individuals with genetically elevated pressure set-points at GWAS-identified loci. At the A allele's beta of ~0.02 mmHg per copy, homozygous carriers accumulate a meaningful additive genetic pressure contribution that compounds with modifiable risk factors like sodium, obesity, and sleep-disordered breathing.

Monitoring with 24-hour ambulatory blood pressure measurement (ABPM) rather than clinic readings captures early nocturnal hypertension — the pattern most predictive of end-organ damage in genetically elevated pressure phenotypes. For women planning pregnancy, early-trimester blood pressure baseline and low-dose aspirin prophylaxis (75–150 mg daily from 12 weeks) represent evidence-based preeclampsia risk reduction strategies endorsed by ACOG and NICE for elevated-risk individuals.

Interactions

PLCE1 rs10882398 shares pathway biology with rs932764 (PLCE1 hypertension susceptibility variant associated with antihypertensive drug response differences between racial groups; PMID:31327267) — both are PLCE1 intronic variants, and their LD relationship and combined effect on PLCE1 expression have not been fully characterized.

The blood pressure associations at rs10882398 overlap with the FGF5 and RGL3 blood-pressure loci co-identified in the same preeclampsia GWAS, suggesting that the genetic architecture of pregnancy hypertension mirrors essential hypertension — multiple additive loci, each contributing a small but real pressure increment, with the cumulative burden materializing clinically during the haemodynamic stress of pregnancy.

Telomeres — the repetitive DNA caps that protect chromosome ends — shorten with every cell division, acting as a biological clock that marks cellular age. The gene TERC encodes the RNA template that the telomerase enzyme uses to rebuild these caps, and the chromosomal region 3q26.2 harboring TERC contains some of the strongest genetic determinants of telomere length discovered through population genetics.

rs10936599 is a regulatory variant near TERC that emerged as the single most significant predictor of leukocyte telomere length in the landmark 2013 genome-wide meta-analysis by Codd and colleagues. Its biology illustrates a striking paradox at the heart of telomere science: the allele that maintains longer telomeres also increases the risk of certain cancers, while the allele linked to shorter telomeres — and accelerated cellular aging — appears to reduce cancer susceptibility.

The Mechanism

rs10936599 sits approximately near the 5'UTR region of TERC in an area that influences how much TERC RNA the cell produces or how stable that RNA is. TERC does not encode a protein — it is the RNA template that TERT (the protein catalytic component) uses to add the TTAGGG repeat sequence back to shortening telomere ends.

The C allele (major, ~75% frequency) is associated with higher TERC mRNA levels and longer telomeres — approximately 117 base pairs more per allele¹¹ 117 base pairs more per allele
from the ENGAGE consortium data in Codd et al. 2013. The T allele (minor, ~25% frequency) appears to reduce TERC expression or activity, resulting in less efficient telomere rebuilding and telomeres that are measurably shorter over a lifetime.

The paradox arises because longer telomeres suppress cellular senescence — the process that normally kills precancerous cells before they can proliferate. Cells with genetically longer telomeres can divide more times before entering senescence, which is protective against age-related organ failure but removes one of the body's natural cancer checkpoints. This is why the C allele (longer telomere) appears in GWAS findings for colorectal cancer, glioma, lung cancer, and multiple sclerosis susceptibility, while the T allele (shorter telomere) increases risk for cardiovascular disease and COPD — diseases driven by premature cellular exhaustion rather than unchecked proliferation.

The Evidence

The definitive characterization of rs10936599 came from a genome-wide meta-analysis of 37,684 individuals with replication in 10,739 more²² genome-wide meta-analysis of 37,684 individuals with replication in 10,739 more
Codd V et al. Identification of seven loci affecting mean telomere length. Nat Genet 2013. The T allele was the strongest single-SNP predictor of shorter telomeres in the entire genome (beta = −0.097, P = 2.54×10⁻³¹), explaining 0.36% of variance in leukocyte telomere length — equivalent to approximately 3.9 years of age-related telomere attrition per T allele.

The same meta-analysis identified rs10936599 as part of a seven-SNP genetic risk score (GRS) for telomere length — a tool now widely used in Mendelian randomization studies to tease apart the causal effects of telomere length from confounders. rs10936599 contributes the largest single weight in this GRS, making it the anchor SNP for genetically determined telomere length in population genetics research.

The earlier 2010 GWAS in 12,409 individuals³³ 2010 GWAS in 12,409 individuals
Codd V et al. Common variants near TERC are associated with mean telomere length. Nat Genet 2010 first established the TERC 3q26 locus as the top genetic determinant of leukocyte telomere length, and rs10936599 tags the strongest signal within this locus.

For cardiovascular health, a prospective study of acute heart failure patients⁴⁴ prospective study of acute heart failure patients
Chen et al. Frontiers in Endocrinology 2021 found that rs10936599 genotype was an independent predictor of 18-month mortality. In the dominant model (CC+CT vs TT), mutant allele carriers had HR 2.84 (95% CI 1.48–5.44, P = 0.001) for death — a clinically significant prognostic effect in patients with established heart disease.

A case-control study in Chinese Han individuals⁵⁵ case-control study in Chinese Han individuals
Li et al. Scientific Reports 2017 found that the C allele at rs10936599 was associated with increased ischemic stroke risk (OR = 1.26, 95% CI 1.00–1.58, P = 0.049). This finding, where the longer-telomere C allele increases stroke risk, reflects the complex pleiotropic effects of telomere length on vascular biology that vary by context, age, and disease stage.

The Longevity-Aging Framing

In the longevity-aging context, the T allele is the primary concern: it reduces telomere maintenance capacity, accelerating the rate at which cells accumulate telomere damage and enter senescence. Each T allele is equivalent to approximately 3.9 years of extra biological aging at the telomere level. TT homozygotes — carrying two T alleles — have telomeres genetically comparable to someone nearly 8 years older.

Critically, the T allele interacts with lifestyle factors that independently shorten telomeres: smoking, chronic inflammation, psychological stress, and oxidative load. For carriers of the T allele, these environmental insults deplete an already smaller telomere reserve.

The C allele (normal for longevity purposes) does carry its own complex biology — the longer-telomere state mildly increases risk for some cancers by reducing cellular senescence as a tumor-suppressive mechanism. This is worth knowing but is a very different clinical concern from accelerated aging.

Interactions

rs10936599 is part of the TERC 3q26.2 locus that also harbors rs12696304 and rs16847897, two other variants associated with telomere length. These SNPs are not in tight linkage disequilibrium and may tag partially independent regulatory effects on TERC expression. Individuals carrying the T allele at rs10936599 alongside risk alleles at rs12696304 (G) or rs16847897 (C) may have compounded reduction in telomere maintenance from the TERC locus.

At the pathway level, rs10936599 interacts with TERT rs2736100 (the catalytic protein component of telomerase). Both TERC and TERT must function adequately for telomere maintenance; individuals with reduced function at both loci face the most pronounced telomere attrition.

rs10936599 is included in the standard seven-SNP Mendelian randomization genetic instrument for telomere length alongside rs2736100, rs7675998, rs9420907, rs8105767, rs755017, and rs11125529 — reflecting its role as the dominant genetic determinant of leukocyte telomere length in the genome.

Your liver is constantly converting cholesterol into bile acids — the detergent-like molecules that emulsify dietary fat and exit the body via the gut. The enzyme that sets the pace for this entire process is cholesterol 7α-hydroxylase¹¹ cholesterol 7α-hydroxylase
CYP7A1 catalyzes the first and rate-limiting step of the classic bile acid synthesis pathway, converting cholesterol to 7α-hydroxycholesterol, encoded by the CYP7A1 gene. The faster this enzyme works, the more cholesterol gets converted to bile acids and cleared, and the lower your LDL tends to be. Variants upstream of CYP7A1 — including rs1125226 — help define haplotypes that collectively tune how much bile acid your liver produces.

The Mechanism

CYP7A1 sits in hepatocyte endoplasmic reticulum membranes and governs the neutral (classic) bile acid pathway²² neutral (classic) bile acid pathway
The classic pathway accounts for ~75% of all bile acid production in humans; the alternative acidic pathway handles the remainder. Its expression is regulated by a network of nuclear receptors: LXRα activates CYP7A1 transcription in response to excess hepatic cholesterol, while FXR (activated by returning bile acids from the gut) represses it as a feedback brake. rs1125226 sits approximately 6.8 kb upstream of the CYP7A1 transcription start site — within the extended promoter/regulatory region — and is a haplotype-tagging SNP for this gene. It was characterised as part of a systematic mapping of CYP7A1's linkage disequilibrium blocks³³ linkage disequilibrium blocks
regions of the genome inherited together more often than chance alone across five population groups.

The rs1125226 A allele co-segregates with specific CYP7A1 promoter haplotypes, of which the well-studied rs3808607 variant is the primary functional site. In hepatocyte assays, the rs3808607 G allele (which travels with certain rs1125226 haplotypes) drives higher CYP7A1 mRNA expression⁴⁴ higher CYP7A1 mRNA expression
Inamine et al. 2013: the G-allele promoter induced significantly higher CYP7A1 expression under both normal and cholestatic conditions than the T allele. The combined two-SNP regulatory model spanning promoter and enhancer spans more than two orders of magnitude in hepatic CYP7A1 expression⁵⁵ two orders of magnitude in hepatic CYP7A1 expression
Wang et al. 2018: only the two-SNP model, not either SNP alone, significantly associated with LDL levels, CAD risk, statin response, and T2D.

The Evidence

A 2023 meta-analysis by Lim et al.⁶⁶ Lim et al.
Lim MYC et al. A meta-analysis of the pooled impact of CYP7A1 single nucleotide polymorphisms on serum lipid responses to statins. Front Genet, 2023 pooled statin-response data and found that CYP7A1 variant carriers had significantly smaller reductions in total cholesterol (WMD −0.17 mmol/L, 95% CI −0.29 to −0.06) and LDL (WMD −0.16 mmol/L, 95% CI −0.26 to −0.05) compared to non-carriers.

Dietary studies add a complementary picture. Wang et al. 2017⁷⁷ Wang et al. 2017
Wang Y et al. Barley β-glucan reduces blood cholesterol levels via interrupting bile acid metabolism. Br J Nutr, 2017 showed that high-molecular-weight barley β-glucan increased bile acid synthesis in all participants, but the effect was "more pronounced" in homozygous G carriers at rs3808607 — the individuals whose CYP7A1 promoter appears most responsive. This genotype-by-diet interaction suggests that dietary cholesterol-lowering strategies targeting bile acid excretion may be especially effective for people whose CYP7A1 is already tuned high.

The earlier Hubacek & Bobkova review⁸⁸ Hubacek & Bobkova review
Hubacek JA, Bobkova D. Role of cholesterol 7alpha-hydroxylase (CYP7A1) in nutrigenetics and pharmacogenetics of cholesterol lowering. Mol Diagn Ther, 2006 summarised the opposing direction of effect: −204CC homozygotes (at rs3808607) showed the greatest cholesterol reduction from dietary changes, while the −204AA homozygotes responded slightly better to statin therapy. This divergence likely reflects the enzyme's feedback relationship with statins — statins upregulate CYP7A1 as a compensatory mechanism, and individuals with higher baseline CYP7A1 activity may have a ceiling effect.

Direct evidence for rs1125226 alone is limited. The Fu et al. 2011 study⁹⁹ Fu et al. 2011 study
Fu L et al. CYP7A1 genotypes and haplotypes associated with hypertension in an obese Han Chinese population. Hypertens Res, 2011 found no significant independent effect of rs1125226 genotype on hypertension susceptibility, though haplotypes combining rs3808607 and rs1125226 alleles showed significant differences. rs1125226 is best interpreted as a haplotype marker that defines which CYP7A1 regulatory environment you carry, rather than as an independent functional variant.

Practical Actions

For A allele carriers whose haplotype co-occurs with lower CYP7A1 activity signatures, a practical strategy is to emphasise dietary routes that maximise bile acid excretion. Soluble fibre from oats, barley (β-glucan), psyllium, and legumes binds bile acids in the gut and forces the liver to convert more cholesterol to replace them — effectively using diet to compensate for a genetically slower enzymatic throttle. LDL response to statin therapy should be monitored, as meta-analytic data suggest carriers may achieve somewhat smaller LDL reductions at standard doses.

For CC homozygotes, the complementary picture holds: dietary interventions targeting bile acid excretion are likely to be especially responsive, while statin response may be modestly blunted relative to the population average.

Interactions

rs1125226 is a haplotype partner to rs3808607, the CYP7A1 A-204C promoter variant. Their combined haplotype structure is the primary lens through which CYP7A1 regulatory variation should be interpreted — no single SNP in this region tells the whole story. Additionally, CYP7A1 operates at the top of the bile acid synthesis cascade; variants in downstream genes (CYP8B1, BSEP/ABCB11, FXR/NR1H4) and in the cholesterol clearance pathway (APOE rs429358, LDLR) can modify the net effect of CYP7A1 haplotype variation on plasma LDL.

The FCRL3¹¹ FCRL3
Fc receptor-like 3; expressed at high levels on B cells and regulatory T cells, where it modulates activation thresholds and autoantibody production through immunoreceptor tyrosine-based inhibitory and activation motifs (ITIMs and ITAMs) gene sits on chromosome 1q23, a region densely populated with immune receptor genes. rs11264799 lies approximately 59 bp from the well-studied rs7528684 promoter variant, placing it squarely in the upstream regulatory landscape of FCRL3. The variant itself does not change the FCRL3 protein — it is classified as an upstream transcript variant — but it exerts a measurable influence on how much FCRL3 is produced in immune cells.

FCRL3 is on the minus strand of chromosome 1; the alleles reported in genome files (C and T) are plus-strand notation. The C allele is the GRCh38 reference and the more common allele globally (~73%); the T allele is the minor variant (~27%) that carries the eQTL signal.

The Mechanism

rs11264799 has been identified as a strong expression quantitative trait locus (eQTL)²² strong expression quantitative trait locus (eQTL)
eQTLs are genetic variants that influence the amount of RNA or protein produced by a nearby gene; they act as natural experiments showing how subtle regulatory changes alter gene dosage in human tissues for FCRL3. In B cells and regulatory T cells, higher FCRL3 expression alters the balance between activation and inhibition: more surface FCRL3 can either amplify or dampen B cell receptor signals depending on the cellular context. The T allele's eQTL effect on FCRL3 expression in lymphoid tissue explains why it has been repeatedly captured in genetic studies of conditions where B cell tolerance is central — IgA nephropathy, autoimmune thyroid disease, and inflammatory arthritis — even though the individual SNP associations are smaller and less consistent than those seen for the closely linked rs7528684 promoter variant.

The T allele is in linkage disequilibrium with rs6427389, a variant that reached genome-wide significance (OR=1.132, P=8.18×10⁻⁹) in a large IgAN GWAS meta-analysis; the authors noted that rs11264799 was the likely functional mediator through its FCRL3 eQTL activity.

The Evidence

The clearest evidence for rs11264799 comes from IgA nephropathy, a condition in which autoantibodies against galactose-deficient IgA1 drive mesangial immune complex deposition and progressive kidney disease. A large Chinese case-control study of 1,750 IgAN patients and 2,500 controls³³ large Chinese case-control study of 1,750 IgAN patients and 2,500 controls
Zhong Z, Feng S, Shi D et al. Association of FCRL3 Gene Polymorphisms with IgA Nephropathy in a Chinese Han Population. DNA Cell Biol 39:154–162, 2020 found rs11264799 significantly associated with IgAN susceptibility after Bonferroni correction, with the T allele linked to altered FCRL3 expression. A subsequent genome-wide meta-analysis across Chinese and European IgAN cohorts⁴⁴ genome-wide meta-analysis across Chinese and European IgAN cohorts
Li M et al. Genome-Wide Meta-Analysis Identifies Three Novel Susceptibility Loci. J Am Soc Nephrol 31:2045–2057, 2020 confirmed the 1q23.1 FCRL3 locus at genome-wide significance, identifying rs11264799 as the key eQTL variant underlying the association signal.

In the broader autoimmune context, a meta-analysis of 34 case-control studies⁵⁵ meta-analysis of 34 case-control studies
Yang Y, Su X, Zhang K, Zhou R. Autoimmunity 46:547–558, 2013 found rs11264799 significantly associated with autoimmune diseases in mixed ethnic subgroups, though associations in individual European or Asian populations were not consistently replicated across diseases. Heterogeneity between studies — different LD structures, disease definitions, and population ancestries — explains why single-study results for this variant are frequently negative even when the eQTL signal at the locus is robust.

For rheumatoid arthritis, multiple sclerosis, and SLE individually, rs11264799 has not shown independent replication in European cohorts; the bulk of disease association evidence for FCRL3 in these conditions is carried by the closely linked rs7528684. The evidence base for rs11264799 specifically is therefore classified as emerging.

Practical Actions

The T allele at rs11264799 acts primarily through altered FCRL3 expression, placing this variant in the same functional context as rs7528684: conditions where B cell hyperactivity and impaired immune tolerance are central. The most directly supported disease link is IgA nephropathy; broader autoimmune connections remain plausible given the eQTL mechanism but are not independently confirmed for this variant.

For TT carriers, the most actionable step is awareness of early IgAN symptoms — particularly recurrent visible haematuria (blood in urine) following upper respiratory infections, which is the hallmark presentation — and periodic urinalysis to detect subclinical proteinuria or microhaematuria before kidney function is affected.

Interactions

rs11264799 is 59 bp from rs7528684 in the FCRL3 upstream region; both variants influence FCRL3 expression and are likely to be in partial linkage disequilibrium. The rs7528684 G allele has the stronger and better-replicated autoimmune association (RA, Graves' disease, Hashimoto's thyroiditis via NF-κB binding), while rs11264799 contributes an additional eQTL layer that may operate semi-independently. Carriers of risk alleles at both loci may have amplified FCRL3 dysregulation compared to carriers of either alone, though direct compound heterozygosity data are not yet published.

Interferon Regulatory Factor 5 (IRF5) is the molecular conductor of the type I interferon symphony — a transcription factor that, when overactive, drives the chronic immune hyperactivation underlying systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis, and Sjögren syndrome. Among the many variants scattered across the IRF5 locus, rs11269962 holds a distinctive position: of all the polymorphisms tested, it shows the strongest statistical association with IRF5 mRNA expression levels by RNA-seq¹¹ strongest statistical association with IRF5 mRNA expression levels by RNA-seq
P=0.002, Fernández-Hernández et al. 2013 — identified from a screen of 26 cis-regulatory candidates across the IRF5 5' region. It sits 2.2 kilobases upstream of the IRF5 transcription start site, within the same 5' regulatory haplotype block as rs729302 and rs13245639, and serves as the third independent functional tag for the protective haplotype architecture at this locus.

The Mechanism

rs11269962 is a 14-base-pair insertion/deletion polymorphism embedded in the IRF5 5' upstream regulatory region. The two alleles — insertion (I, the major allele) and deletion (D, the minor allele) — create structurally different chromatin environments that interact differentially with nuclear transcription factors.

In electrophoretic mobility shift assays (EMSA)²² electrophoretic mobility shift assays (EMSA)
A technique that detects protein–DNA binding by observing whether a DNA fragment "shifts" to a slower mobility when complexed with nuclear proteins using WIL2-NS B lymphoblastoid nuclear extracts, the insertion (I) allele showed a specific delayed band absent with the deletion allele — meaning the insertion sequence recruits a transcription factor that the deletion sequence does not. Paradoxically, luciferase reporter assays showed that the construct carrying the insertion allele produced lower transcriptional output than the deletion-allele construct, indicating that the bound factor is repressive rather than activating. The deletion allele, by removing this binding site, releases this repression and increases basal IRF5 transcription in isolation.

At the haplotype level, however, the net effect reverses. The deletion (D) allele sits predominantly on haplotypes H2 and H3 — the low-expression protective haplotypes that correlate with reduced IRF5 mRNA and lower SLE susceptibility — while the insertion (I) allele is enriched on neutral-to-risk haplotypes. This haplotype-level effect reflects the combined regulatory architecture of all variants in the block rather than the isolated effect of rs11269962 alone. The rs11269962 signal is most meaningfully interpreted in its haplotype context: deletion allele → protective haplotype³³ deletion allele → protective haplotype
The D allele has r²=0.36 with rs729302-C (protective) in European samples but is below r²=0.05 in Asian and African populations — it partially tags the protective block but also captures independent regulatory variation.

The Evidence

Fernández-Hernández et al. (2013) performed a systematic functional screen of 26 cis-regulatory candidate polymorphisms across the IRF5 5' region. Only four passed dual criteria of allele-specific EMSA binding and reporter gene expression differences: rs11269962, rs13245639, the CGGGG promoter indel, and rs12706860. Among these, rs11269962 stood out as the variant most significantly associated with IRF5 mRNA levels measured directly by RNA-seq — the gold standard for quantifying transcript abundance. This is a functionally important distinction: most IRF5 variants are identified through disease association or LD tagging; rs11269962 was identified through its direct impact on transcript levels.

The broader protective haplotype block that rs11269962 tags was established in the 14-cohort European SLE study by Ferreiro-Neira et al.⁴⁴ 14-cohort European SLE study by Ferreiro-Neira et al.
1,383 SLE cases, 1,614 controls; independent protective signal from the 5' IRF5 region, P<10⁻⁶, distinct from the 3' susceptibility signal at rs10488631 (P<10⁻¹⁷). The comprehensive haplotype study by Graham et al. further refined this picture, showing that haplotypes H2 and H3 — both carrying the deletion allele at the rs11269962 position — showed odds ratios of approximately 0.79 and 0.89 for SLE⁵⁵ odds ratios of approximately 0.79 and 0.89 for SLE
Relative to the population average haplotype frequency, indicating meaningful disease protection.

A notable population stratification exists: the r² between rs11269962 and rs729302 is 0.36 in European samples but below 0.05 in Asian and African populations, meaning the haplotype block architecture differs substantially across ancestries. This weak inter-population LD indicates that rs11269962 captures regulatory variation that is partially independent of rs729302's protective signal — it is not simply a redundant tag but an additional regulatory dimension of the protective haplotype system.

Practical Implications

Because rs11269962 is a 14-bp indel, it is not covered by standard consumer genotyping chips (23andMe v3/v4/v5). Accurate genotyping requires whole-genome sequencing (WGS) with structural variant calling. Individuals with WGS data can use this variant for a more complete picture of their IRF5 regulatory haplotype, particularly when combined with rs729302 and rs13245639 genotypes.

The deletion (D) allele is the protective allele: it tags the low-expression IRF5 haplotypes associated with reduced autoimmune susceptibility. Homozygous DD individuals have both gene copies running on a protective haplotype background; ID heterozygotes carry one protective and one neutral-to-risk copy; II homozygotes carry no deletion-tagged protective haplotype at this specific regulatory locus.

This variant's value is primarily as a functional anchor within the IRF5 protective haplotype architecture. It does not standalone as a clinical diagnostic variant but provides mechanistic context for why the rs729302 protective haplotype works: the upstream regulatory region carries multiple coordinated functional changes, of which rs11269962 represents the single strongest mRNA-expression signal.

Interactions

rs11269962 belongs to the same 5' IRF5 regulatory haplotype block as rs729302 and rs13245639, though with only moderate LD with rs729302 (r²=0.36 in Europeans) and effectively independent in Asian and African populations. The IRF5 locus has a three-block regulatory architecture: the 5' protective block (rs729302, rs13245639, rs11269962, CGGGG indel), the exon 1 splicing block (rs2004640), and the 3' risk block (rs10488631). rs11269962 operates within the 5' protective block but captures independent regulatory variation that rs729302 alone does not fully explain.

The IRF5 expression it influences feeds downstream into the STAT4 signalling pathway (rs7574865), which amplifies cellular responsiveness to type I interferons. Lower IRF5 expression from deletion-allele haplotypes reduces the initial interferon production signal; low-risk STAT4 genotypes then further reduce the amplification of that signal — creating a cumulative dampening of the interferon axis.

Interleukin-1 beta (IL-1β) is one of the most potent pro-inflammatory cytokines in the human immune system¹¹ one of the most potent pro-inflammatory cytokines in the human immune system
IL-1β activates NF-κB signaling, drives fever, induces acute phase proteins, promotes neutrophil recruitment, and directly stimulates bone resorption — all fundamental to both protective immunity and inflammatory disease. The IL1B gene encodes this cytokine on chromosome 2, and the rs1143634 variant at exon 5 position +3954 presents an unusual biological puzzle: a synonymous mutation — one that preserves the amino acid sequence — that nonetheless changes how much IL-1β protein the body produces²² a synonymous mutation — one that preserves the amino acid sequence — that nonetheless changes how much IL-1β protein the body produces
The F105F substitution (Phe→Phe) is silent at the protein level but functionally loud at the secretion level.

The Mechanism

The +3954C>T variant (rs1143634) is located in exon 5 of IL1B, in the region encoding the mature IL-1β protein's domain critical for receptor binding. Despite causing no amino acid change at position 105 (phenylalanine is retained regardless of C or T), carriers of the T allele produce substantially more IL-1β protein after immune stimulation³³ carriers of the T allele produce substantially more IL-1β protein after immune stimulation
In a study of aseptic implant loosening, T allele carriers had plasma IL-1β levels of 11.79 pg/mL versus 2.11 pg/mL in CC homozygotes after stimulation — a 5.6-fold difference.

The mechanism by which a synonymous codon change alters protein secretion likely operates at the post-transcriptional level. Synonymous variants can alter mRNA secondary structure, codon usage optimization, or regulatory element binding within the coding sequence⁴⁴ alter mRNA secondary structure, codon usage optimization, or regulatory element binding within the coding sequence
These effects can influence mRNA stability, translation efficiency, or protein folding — and for IL-1β, which requires caspase-1 cleavage for secretion, subtle conformational changes in the precursor protein could plausibly accelerate or facilitate the secretion process. In vitro studies show that the T allele leads to measurably higher IL-1β release from lipopolysaccharide-stimulated immune cells compared to the C allele.

This variant is distinct from the better-known promoter variants in IL1B: rs16944 (-511C>T) and rs1143627 (-31T>C)⁵⁵ rs16944 (-511C>T) and rs1143627 (-31T>C)
These two promoter variants regulate IL-1β transcription; rs1143634 instead appears to affect post-translational secretion or processing, providing an independent second tier of IL-1β output control. A person who carries high-producing alleles at multiple IL1B loci may have compounded elevation of IL-1β output.

The Evidence

The strongest and most consistent evidence links rs1143634 to periodontal disease. A meta-analysis of 54 case-control studies encompassing 9,376 participants⁶⁶ meta-analysis of 54 case-control studies encompassing 9,376 participants
Association between the rs1143634 polymorphism in interleukin-1B and chronic periodontitis. Journal of Periodontal Research, 2018 found the T allele significantly associated with chronic periodontitis risk (OR 1.35, 95% CI 1.24–1.48; p < 0.00001). Stratified analyses confirmed the association in Caucasian, Asian, and mixed populations, though not in African ancestry cohorts.

The aseptic joint loosening study⁷⁷ aseptic joint loosening study
IL-1β gene (+3954C/T) and NOS2 polymorphisms associate with early aseptic loosening of arthroplasties. Scientific Reports, 2022 provided some of the most compelling functional evidence: patients with the TT genotype showed a 3.7-fold higher hazard of requiring revision surgery within 5 years (HR 3.70, 95% CI 1.27–10.75), with the elevated IL-1β levels directly driving peri-implant bone resorption. This study confirmed the secretion phenotype rather than just disease association.

For cancer risk, an updated meta-analysis of 44 studies (18,645 cancer patients, 22,882 controls)⁸⁸ updated meta-analysis of 44 studies (18,645 cancer patients, 22,882 controls)
Role of IL-1β rs1143634 (+3954C>T) polymorphism in cancer risk. International Journal of General Medicine, 2021 found the T allele associated with modestly elevated overall cancer risk (allelic model OR 1.08). Gastric cancer, breast cancer, and multiple myeloma showed the most consistent signals in subgroup analyses.

In inflammatory bowel disease, IL1B gene polymorphisms including the exon 5 variant were shown to influence the course and severity of IBD in a study of 96 UC and 98 Crohn's patients⁹⁹ IL1B gene polymorphisms including the exon 5 variant were shown to influence the course and severity of IBD in a study of 96 UC and 98 Crohn's patients
IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Gut, 2000, establishing a role for this variant in gastrointestinal inflammatory disease progression rather than susceptibility alone.

A notable negative finding: the T allele is not associated with aggressive periodontitis (OR 0.99, 95% CI 0.79–1.23 in a 25-study meta-analysis) — the association is specific to chronic periodontitis. This distinction matters clinically: aggressive and chronic periodontitis have different etiologies and risk profiles, and the IL-1β elevation associated with this variant appears to drive the sustained chronic inflammatory pattern rather than acute-onset aggressive disease.

Practical Actions

Elevated IL-1β production from this variant is not inevitably harmful — it is a quantitative trait that becomes clinically relevant under specific conditions. The most actionable implications:

Dental health: Carriers of one or two T alleles have meaningfully elevated periodontal risk. The T allele is particularly dangerous in combination with smoking, where the risk amplifies substantially. The variant provides a genetic basis for prioritizing periodontal care beyond standard recommendations.

Inflammatory conditions: Elevated baseline IL-1β production may accelerate inflammation-driven tissue damage in contexts ranging from joint prostheses to gastrointestinal mucosa. Conditions where IL-1β is a known mediator — including gout, IBD flares, and peri-implant inflammation — may be more severe in T allele carriers.

Cancer context: The modest cancer risk elevation (OR ~1.08) is not sufficient to change standard screening protocols, but it reinforces the importance of anti-inflammatory strategies and standard cancer screening adherence.

Interactions

rs1143634 is part of the IL1B locus on chromosome 2q14.1, which also encodes IL1A, and is co-located with the IL1RN gene encoding the IL-1 receptor antagonist. The promoter variants rs16944 (−511) and rs1143627 (−31) regulate IL-1β transcription via different mechanisms from rs1143634. A person carrying risk alleles at both the promoter level (rs16944) and the exon 5 level (rs1143634) may have compounded IL-1β output — both more transcript and more efficient secretion of the protein.

Interaction with IL1RN rs419598 (the IL-1 receptor antagonist gene) is biologically important: IL-1Ra counterbalances IL-1β by competing for the IL-1 receptor without signaling. Carrying the rs1143634 T allele (high IL-1β) alongside low-producing IL-1Ra variants may amplify net IL-1 signaling substantially.

The composite IL-1 genotype combining IL1A rs1800587 and IL1B rs1143634 was shown to have a 2.84-fold risk of chronic periodontitis in smokers (OR 4.43 in male smokers, OR 6.00 in female smokers)¹⁰¹⁰ a 2.84-fold risk of chronic periodontitis in smokers (OR 4.43 in male smokers, OR 6.00 in female smokers)
Interaction of IL1B and IL1RN polymorphisms, smoking, gender and ethnicity with aggressive and chronic periodontitis susceptibility. J Clin Periodontol, 2016, illustrating that single-variant effects are substantially potentiated in this combined context.

Endometriosis affects an estimated 10% of reproductive-age women and remains one of the most under-diagnosed causes of chronic pelvic pain and infertility. The condition is estrogen-dependent: ectopic lesions generate their own local estrogen supply through elevated aromatase activity, and this autocrine estrogen loop drives lesion proliferation and immune evasion. GREB1 — Growth Regulation by Estrogen in Breast Cancer 1 — encodes a nuclear co-factor that physically binds steroid hormone receptors and amplifies their transcriptional output¹¹ GREB1 — Growth Regulation by Estrogen in Breast Cancer 1 — encodes a nuclear co-factor that physically binds steroid hormone receptors and amplifies their transcriptional output
Chadchan et al. Nature Communications, 2024.

rs11674184 is an intronic variant in GREB1 at chromosome 2p25.1 that was identified as a statistically independent endometriosis risk signal in the landmark 2023 Rahmioglu Nature Genetics multi-ancestry GWAS meta-analysis. Critically, it is not simply a proxy for the previously described rs13394619 GREB1 variant already in the GeneOps database: the two variants have r²=0.65 in European populations — moderate linkage disequilibrium, not the r²>0.8 threshold that would indicate redundancy. They tag different aspects of the GREB1 regulatory landscape.

The GRCh38 reference allele (T) is the risk allele here, with the less common G allele conferring protection. This is the reverse of the intuitive direction — the T allele at rs11674184 is common (~63% globally) and constitutes the risk-conferring genotype.

The Mechanism

GREB1 operates as a context-dependent steroid hormone cofactor. In normal endometrium during the secretory phase, GREB1 binds the progesterone receptor and promotes downstream decidualization targets including WNT4 and FOXO1A²² In normal endometrium during the secretory phase, GREB1 binds the progesterone receptor and promotes downstream decidualization targets including WNT4 and FOXO1A
Chadchan et al. 2024. In endometriotic lesions, where estrogen dominates, GREB1 switches roles to act as an estrogen receptor cofactor — amplifying estrogen-driven gene expression and ectopic cell proliferation. GREB1 mRNA and protein are significantly elevated in peritoneal endometriotic lesions compared with eutopic endometrium from unaffected women³³ GREB1 mRNA and protein are significantly elevated in peritoneal endometriotic lesions compared with eutopic endometrium from unaffected women
Pellegrini et al. Fertility and Sterility, 2012. Mouse knockout models with GREB1 deletion show substantially reduced ectopic lesion volume and mass.

The intronic rs11674184 variant lies within c.901+577 of the GREB1 transcript. Its modest CADD score (~7.7) and low evolutionary constraint (GERP −0.61) suggest limited direct functional impact on the protein, consistent with a regulatory tag SNP. Fine-mapping of the GREB1 locus by Fung et al. 2015 (Human Reproduction)⁴⁴ Fung et al. 2015 (Human Reproduction)
Fung et al. Fine mapping of GREB1 in endometriosis, 2015 identified multiple intronic variants at this locus with independent association signals, suggesting the region contains at least two distinct regulatory elements influencing GREB1 expression or splicing in endometrial tissue.

The Evidence

Rahmioglu et al. 2023 (Nature Genetics)⁵⁵ Rahmioglu et al. 2023 (Nature Genetics) conducted the largest endometriosis GWAS to date, incorporating data from 23andMe and major biobanks across European and East Asian populations. rs11674184 reached genome-wide significance for all endometriosis (risk allele T: OR=1.13, 95% CI 1.10–1.15, P=3×10⁻¹⁷) and showed a stronger association for confirmed Stage III/IV disease (OR=1.16, P=6×10⁻⁹), consistent with the pattern seen for the nearby rs13394619 where the GREB1 locus effect is enriched in moderate-to-severe disease.

A small Greek case-control study (166 cases, 168 controls) by Matalliotaki et al. 2019 (Molecular Medicine Reports)⁶⁶ Matalliotaki et al. 2019 (Molecular Medicine Reports)
Matalliotaki et al. 2019 found no association for rs11674184, which the authors acknowledged was "one of the most consistently associated SNPs with endometriosis in European ancestry populations." The non-significant result in this study is consistent with insufficient statistical power rather than a true null: the effect size (OR≈1.13) and a sample of 166 cases would require approximately 2,000+ cases to reach genome-wide significance. The Rahmioglu 2023 finding with many thousands of cases is authoritative on this point.

The T allele frequency shows marked ancestry stratification: approximately 0.62 in Europeans, 0.57 in East Asians, but only approximately 0.24 in African populations — meaning GG protective homozygotes are far more common in women of African ancestry (~58%) than in Europeans (~14%).

Practical Implications

Carrying T alleles at rs11674184 raises endometriosis susceptibility, with OR≈1.13 per allele across the full endometriosis phenotype and OR≈1.16 for Stage III/IV. As with all common GWAS variants, these are population-level probability shifts rather than deterministic predictions. The key actionable implication is recognizing and acting on symptoms promptly. Endometriosis diagnostic delay averages 7–9 years across many healthcare systems, driven by normalization of menstrual pain. Women carrying the TT genotype — with the highest common genetic load at this locus — have the strongest motivation to pursue early specialist evaluation rather than accepting pain as normal.

For TT carriers in whom fertility is a consideration, the particular enrichment of this variant's effect at Stage III/IV disease supports proactive ovarian reserve assessment: moderate-to-severe endometriosis, especially ovarian endometriomas, is the mechanism through which endometriosis most directly impairs fertility.

Interactions

rs13394619 (GREB1): The other replicated intronic GREB1 variant in the GeneOps database. The two variants have r²=0.65 in European populations — they share roughly 65% of their variance but are not redundant. Women carrying risk alleles at both rs11674184 (TT or GT) and rs13394619 (GG or AG) may represent a subgroup with elevated cumulative GREB1-pathway genetic load. No formal published study has tested the joint effect of both variants in the same sample; pending such analysis, the individual effects should be considered as partially overlapping but not identical signals.

For supervisor compound action proposal: women carrying the T risk allele at rs11674184 (TT or GT) AND the G risk allele at rs13394619 (GG or AG) carry both GREB1 locus signals simultaneously. The combined recommendation would be: lower threshold for specialist gynecological referral, earlier baseline ovarian reserve testing (AMH + antral follicle count), and proactive fertility counseling. Evidence level: moderate (both independently established at the GREB1 locus; combined effect inferred from consistent additive direction but LD of r²=0.65 means they partially overlap; formal joint analysis not yet published).

rs12700667 (7p15.2, HOXA locus): The other major replicated endometriosis GWAS locus, operating through regulation of HOXA10/HOXA11 — distinct biological pathway from GREB1. Both loci show independent additive effects on endometriosis risk in GWAS meta-analyses, both show stronger signals for Stage III/IV disease, and women carrying risk alleles at both may represent the highest-risk common-variant group identifiable today.

Every cell in your body continuously breaks down and recycles old molecular scaffolding — including glycosaminoglycans¹¹ glycosaminoglycans
Long sugar-chain molecules embedded in cartilage, bone, and connective tissue that give these tissues their structural properties, such as keratan sulfate and chondroitin-6-sulfate. This recycling happens inside lysosomes, tiny cellular recycling compartments, and requires a precise sequence of enzymes. The GALNS gene encodes N-acetylgalactosamine-6-sulfate sulfatase²² N-acetylgalactosamine-6-sulfate sulfatase
EC 3.1.6.4 — an enzyme that removes sulfate groups from the keratan sulfate and chondroitin-6-sulfate sugar chains as they are broken down step by step, one of those critical enzymes. When GALNS is deficient, these glycosaminoglycans accumulate in lysosomes, distorting cells and progressively destroying cartilage and bone. The result is Mucopolysaccharidosis Type IVA (MPS IVA), also known as Morquio syndrome A.

The rs118204437 A allele (c.1156C>T on the coding strand; G>A on the plus genomic strand) changes arginine to cysteine at protein position 386. This is the single most frequently reported GALNS pathogenic variant worldwide, found in approximately 5% of all mutant GALNS alleles in the global literature — and in up to 32.5% of alleles from Latin American cohorts, consistent with a founder effect³³ founder effect
A founder effect occurs when a small ancestral population carrying a mutation gives rise to a larger population, concentrating that mutation at a higher frequency than in the general global population.

The Mechanism

The arginine at position 386 sits in the catalytic core of the GALNS enzyme⁴⁴ catalytic core of the GALNS enzyme
Structural analyses show Arg386 is a buried residue that stabilizes the substrate-binding pocket; its replacement by cysteine disrupts this architecture through changes in charge, polarity, and disulfide-bond potential. Biochemical studies confirm that the Arg386Cys substitution produces no detectable residual enzyme activity — placing it firmly in the severe phenotype category. Patients homozygous for R386C, or compound heterozygous for R386C paired with another null allele, typically present with the full severe form of MPS IVA: progressive skeletal dysplasia, short stature, joint hypermobility, corneal clouding, and cardiorespiratory involvement. A rat model was constructed by engineering the equivalent substitution (Arg388Cys) into the rodent GALNS gene, and it faithfully recapitulates the human skeletal and non-skeletal disease phenotype.

Because GALNS is encoded on the minus strand of chromosome 16, the coding-strand notation (c.1156C>T) and the plus-strand genomic notation (G>A at chr16:88,824,853) appear as complements of each other. Genome files from WGS or consumer genotyping report the plus-strand allele (G reference, A alternate).

The Evidence

Morrone et al. (2014)⁵⁵ Morrone et al. (2014)
Morrone A et al. Morquio A syndrome-associated mutations: a review of alterations in the GALNS gene and a new locus-specific database. Hum Mutat, 2014 curated 1,091 GALNS alleles from the global literature and identified Arg386Cys as the single most common, accounting for 5% of all alleles. It was distributed across 30 countries, with the highest concentration in Spain (25% of Spanish patient alleles), Argentina (11%), and China (9%). Its worldwide distribution and high relative frequency point to both ancient founder events and recurrent de-novo mutation at a CpG-adjacent site.

Tomatsu et al. (2005)⁶⁶ Tomatsu et al. (2005)
Tomatsu S et al. Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). Hum Mutat, 2005 documented the broader GALNS mutation landscape in 148 unique alleles, confirming that Arg386Cys is one of the three mutations exceeding 5% prevalence, and that CpG-dinucleotide transitions (which include this mutation's mechanism) account for 26% of all GALNS pathogenic changes.

A large genotype-phenotype study by Yi et al. (2022)⁷⁷ Yi et al. (2022)
Yi Y et al. Investigation of GALNS variants and genotype-phenotype correlations in a large cohort of patients with mucopolysaccharidosis type IVA. J Inherit Metab Dis, 2022 analyzing 108 MPS IVA patients established that buried-residue missense variants (the class to which R386C belongs) drive severe phenotype in 92% of cases, providing a structural rationale for genotype-based prognosis.

ClinVar (Variation ID 700) lists 14 submissions from major genetics laboratories on four continents — Labcorp Genetics, Baylor Genetics, University of Padova, and Shriners Hospital — all independently classifying the variant as Pathogenic or Likely Pathogenic (2-star review status, no conflicts, last updated January 2026).

Practical Actions

MPS IVA has no cure, but the disease can be actively managed. The FDA approved elosulfase alfa (Vimizim), a recombinant form of GALNS enzyme, in February 2014. Administered weekly at 2 mg/kg IV, it reduces urinary keratan sulfate (a disease biomarker) by ~53% sustained over 5+ years of real-world follow-up, and a phase III randomized trial demonstrated a statistically significant improvement in six-minute walk test distance (+22.5 m, 95% CI 4–41 m) versus placebo. Early initiation before irreversible skeletal damage maximizes benefit.

Asymptomatic heterozygous carriers (GA genotype) require no personal clinical intervention, but genetic counseling is recommended before family planning. Each child of two confirmed carriers has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected. Prenatal and preimplantation genetic testing are available once pathogenic variants are confirmed in both parents.

Interactions

MPS IVA is a monogenic recessive disease: the clinical outcome is determined primarily by whether a person carries two loss-of-function GALNS alleles (compound heterozygous or homozygous). Arg386Cys paired with a second null allele (frameshift, nonsense, or splice site) typically results in the same severe phenotype as homozygous R386C, because both copies of GALNS are non-functional. Compound heterozygosity with attenuated missense alleles (those retaining 1–13% residual activity) can produce intermediate or mild phenotypes. Assessment of the second allele is therefore critical for prognosis in affected individuals.

The kidneys manage roughly two-thirds of daily uric acid excretion, and they accomplish this through a precise interplay of transporters on the proximal tubule epithelium. On the apical (urine-facing) membrane, proteins export uric acid from tubular cells into the tubular lumen for elimination; on the basolateral side, others reclaim it from urine back into the bloodstream. NPT1¹¹ NPT1
sodium-dependent phosphate transport protein 1, encoded by SLC17A1, sits on the apical membrane and functions as a urate efflux transporter — it pumps uric acid out of tubular cells into urine. rs1183201 is an intronic variant in SLC17A1 that tags a haplotype block spanning the SLC17A1–SLC17A3–SLC17A4 gene cluster on chromosome 6; it is in high linkage disequilibrium (r² = 0.97) with rs1165205 in the nearby SLC17A3 gene, so it captures genetic variation across this entire renal secretory locus.

The Mechanism

NPT1 is primarily known as a phosphate-sodium cotransporter in the brush border membrane of kidney proximal tubule cells, but functional studies demonstrate that it also mediates significant urate transport. Acting as part of a broader "urate transportsome"²² "urate transportsome"
a multiprotein complex coordinating bidirectional urate movement at the proximal tubule apical membrane, NPT1 opposes the major reabsorptive transporter URAT1 (SLC22A12). Variants that reduce NPT1 efflux activity shift the reabsorption–secretion balance toward retention, raising the serum urate setpoint.

The functional link between rs1183201 and transporter activity is illuminated by a neighbouring missense variant, rs1165196 (T269I, in LD with rs1183201), which encodes a gain-of-function NPT1 that exports more urate than the wild-type protein³³ more urate than the wild-type protein
Sakiyama et al. 2016: NPT1 I269T variant increased urate transport without altering membrane expression, consistent with enhanced transport kinetics. This confirms that altered NPT1 activity is the biological signal at this locus, even though rs1183201 itself is intronic and likely acts by modifying expression or splicing of SLC17A1 (and possibly SLC17A3) rather than changing protein sequence directly.

The Evidence

The association of rs1183201 with serum uric acid is robustly established. A meta-analysis of 28,141 Europeans across 14 genome-wide association studies identified rs1183201 as genome-wide significant for serum urate (p = 3.0×10⁻¹⁴)⁴⁴ genome-wide significant for serum urate (p = 3.0×10⁻¹⁴)
Kolz et al. 2009, PLoS Genetics; nine independent urate loci identified, including SLC2A9, ABCG2, and SLC17A1. Each copy of the protective A allele lowers serum uric acid by 0.062 standard deviation units (approximately 0.05–0.08 mg/dL), with homozygous AA individuals having the lowest serum urate and TT homozygotes the highest.

Independent replication confirmed the gout association. In 971 New Zealand gout cases and 1,742 controls from Caucasian and Polynesian cohorts, the protective allele showed OR 0.67 in Caucasians (p = 3.0×10⁻⁶) and OR 0.74 in Polynesians (p = 3.0×10⁻³)⁵⁵ the protective allele showed OR 0.67 in Caucasians (p = 3.0×10⁻⁶) and OR 0.74 in Polynesians (p = 3.0×10⁻³)
Hollis-Moffatt et al. 2012, Arthritis Research & Therapy — genome-wide significance for gout risk when both cohorts were combined. In Chinese Han males (622 gout cases, 917 controls), the protective allele showed OR 0.572 (p = 1.39×10⁻⁷) for gout and was also significantly associated with serum uric acid concentrations⁶⁶ OR 0.572 (p = 1.39×10⁻⁷) for gout and was also significantly associated with serum uric acid concentrations
Zhou et al. 2015, BMC Medical Genetics. The consistency across European, Polynesian, and East Asian populations gives this locus strong evidence confidence.

Practical Actions

Elevated serum urate resulting from reduced renal secretion capacity is particularly responsive to dietary purine management. Unlike SLC2A9 or ABCG2 variants (which affect reabsorption), NPT1 reduction is on the secretion side: the kidney is less able to push urate out. Reducing the input — dietary purine load — directly offsets this secretory deficit. High-purine foods (red meat, organ meats, shellfish) raise uric acid production fastest; fructose-sweetened beverages increase uric acid synthesis independently of purine content and should be specifically targeted.

Serum uric acid monitoring is the most direct way to establish your personal setpoint and detect early hyperuricemia before the first gout flare. TT homozygotes should aim for a serum urate target below 6.0 mg/dL (360 µmol/L), the threshold below which monosodium urate crystals dissolve. AT heterozygotes have an intermediate risk and benefit from periodic monitoring, especially during weight gain or increased alcohol intake, which both raise serum urate.

Vitamin C supplementation has specific evidence in the uric acid context: at 500–1,000 mg daily it lowers serum urate by approximately 0.5 mg/dL through competitive inhibition of renal urate reabsorption — an effect that partially compensates for reduced secretory capacity at this locus.

Interactions

rs1183201 operates at the secretory arm of renal urate handling. The most clinically relevant interaction is with rs2231142 in ABCG2 — the breast cancer resistance protein that drives the second major apical secretion pathway for urate. ABCG2 variants dramatically reduce secretion (Q141K in rs2231142 reduces ABCG2 activity by ~50%), and combined SLC17A1 + ABCG2 impairment compresses both secretory routes simultaneously, producing substantially higher serum urate than either variant alone. This compound effect is most relevant in East Asian populations, where both variants are common.

There is also documented LD with rs1165205 (SLC17A3) and potential regulatory co-variation within the SLC17A1/SLC17A3/SLC17A4 gene cluster. The functional significance of SLC17A3 and SLC17A4 in urate handling is less well-characterized than SLC17A1, but the linked haplotype likely encompasses regulatory variation across all three genes.

Deep inside chromosome 19 lies a variant that, for most of human history, has gone entirely unnoticed — yet it sits in a gene that orchestrates how immune cells process and deploy genetic information during inflammation. HNRNPUL1 (heterogeneous nuclear ribonucleoprotein U-like 1) is an RNA-binding protein expressed at especially high levels in macrophages, monocytes, and the immune cells that patrol arterial walls. The rs11881940 variant is intronic — it doesn't change any protein sequence — but the A allele, carried by [roughly 72% of Europeans as homozygotes | the minor T allele reaches only 11.8% frequency in Europeans and is extremely rare in African and South Asian populations], was one of the first variants outside the canonical cardiovascular pathways to show replicable association with early-onset myocardial infarction.

The Mechanism

HNRNPUL1 belongs to the heterogeneous nuclear ribonucleoprotein family — a class of proteins that bind pre-mRNA in the nucleus and direct its splicing, stability, and transport. Studies in zebrafish with HNRNPUL1 loss-of-function mutations found that the gene governs the splicing of at least 76 other transcripts and the expression of over 1,500 downstream genes, including pathways regulating ubiquitination, cell cycle, and protein turnover. [| Lalonde et al. 2022 (PMC9073674): HNRNPUL1 zebrafish mutants show 76 splicing changes and 1,575 differentially expressed genes]

The [Human Protein Atlas | proteinatlas.org/ENSG00000105323-HNRNPUL1] shows that HNRNPUL1 is particularly enriched in immune tissues: bone marrow, thymus, lymph nodes, and tonsil show the highest RNA expression, and single-cell data reveal especially high expression in monocyte progenitors (198.8 nCPM), innate lymphoid cells (209.3 nCPM), and macrophages (104 nCPM). It is also expressed in heart muscle (70.9 nTPM) and blood vessels (85.9 nTPM). This expression profile positions HNRNPUL1 squarely within the cellular machinery that governs how macrophages respond to pro-inflammatory signals in arterial walls — the same macrophages that form foam cells and atherosclerotic plaques.

The rs11881940 A-allele is intronic and does not produce an amino acid change. Its functional effect likely operates through altered pre-mRNA splicing of HNRNPUL1 itself or nearby transcripts, modifying the levels of functionally relevant RNA isoforms in immune and vascular cells. A separate GWAS identified that an eQTL near the CYP2F1 locus (rs12459996) influences HNRNPUL1 expression in blood, supporting the idea that HNRNPUL1 expression levels — not protein structure — are the mechanism by which variants in this region affect cardiovascular risk.

The Evidence

The original discovery study by Shiffman et al. 2006¹¹ Shiffman et al. 2006
Shiffman D et al. Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction. Arterioscler Thromb Vasc Biol. 2006;26(7):1613-8 used a gene-centric association approach across cardiovascular candidate genes. The HNRNPUL1 A-allele emerged with OR 1.92 (95% CI 1.28–2.86, P=0.0043) for early-onset myocardial infarction — a striking effect size for a common intronic variant.

Independent replication came from van der Net et al. 2008²² van der Net et al. 2008
van der Net JB et al. Replication study of 10 genetic polymorphisms associated with coronary heart disease in a specific high-risk population with familial hypercholesterolemia. Eur Heart J. 2008;29(18):2195-201, who genotyped 2,145 Dutch familial hypercholesterolemia (FH) patients — individuals already at extreme CHD risk — and confirmed HR 1.27 (95% CI 1.07–1.51, P=0.007) for coronary events. Among the ten polymorphisms tested, rs11881940 was one of only four to replicate. Critically, the association held after adjustment for hypertension, diabetes, BMI, and lipid levels, indicating the risk is not simply mediated by traditional risk factors. Within the FH cohort, the genotype distribution was TT 2.3%, AT 26.0%, AA 71.7% — meaning most patients carried the risk genotype.

A 2020 GWAS for alcohol-related liver cirrhosis also identified HNRNPUL1 as a susceptibility locus (via a nearby SNP rs15052), further supporting the gene's role in tissue-damage and inflammatory responses beyond the heart. [| Innes et al. 2020: MARC1 and HNRNPUL1 variants associated with alcohol-related cirrhosis risk]

The evidence level is rated moderate: there are two consistent human studies with replication, a plausible immune-cell expression mechanism, and no contradicting large-scale null results. However, the variant has not yet appeared as a genome-wide significant hit in the multi-million participant CAD meta-analyses (CARDIoGRAM, MVP), which use broader case definitions that may dilute the early-onset specific signal.

Practical Actions

Because the A-allele risk is specifically observed in early-onset MI — defined as myocardial infarction before age 55 in men and 65 in women — the most directly evidence-grounded action is earlier and more structured coronary risk assessment. For AT heterozygotes, the modest elevated HR (approximately 1.15–1.27 in replication) supports awareness and regular lipid and inflammatory marker monitoring. For AA homozygotes, who carry the highest burden and are the majority of the population, the 27–61% increased CHD hazard (dose-response from heterozygosity to homozygosity in the van der Net cohort) justifies earlier cardiovascular risk stratification.

High-sensitivity CRP (hs-CRP) is a practical biomarker for the macrophage-driven inflammatory mechanism this variant is associated with. Coronary artery calcium (CAC) scoring provides direct anatomical assessment of subclinical atherosclerosis and is particularly informative for asymptomatic individuals with genetic risk factors but intermediate Framingham scores.

Interactions

The replication cohort in van der Net 2008 consisted of familial hypercholesterolemia patients, which suggests the HNRNPUL1 A-allele may amplify risk when combined with already-elevated LDL — the combination of high cholesterol substrate with pro-inflammatory macrophage activity being particularly atherogenic. There is currently no published compound genotype analysis, but pathway logic supports heightened vigilance in individuals who carry the HNRNPUL1 A-allele together with high LDL-driving variants (e.g. LDLR, APOB, PCSK9 risk variants).